Takeda Completes Acquisition of ...(are statements thatcould be deemed forwa...),Health

Date:5/14/2008

are statements that could be deemed forward-looking statements, including: any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause results to differ from expectations include: Takeda's ability to successfully integrate the two companies and their products; customer acceptance of the companies' combined products, Takeda's ability to retain key employees; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, licensees, other business partners or governmental entities; other business effects, including the effects of industry, economic or political conditions outside of Millennium's or Takeda's control; transaction costs; actual or contingent liabilities; and other risks and uncertainties discussed in documents filed with the U.S. Securities and Exchange Commission by Millennium, as well as the tender offer documents filed by Mahogany Acquisition Corp. and the Solicitation/Recommendation Statement filed by Millennium. Neither Millennium nor Takeda undertakes any obligation to update any forward-looking statements as a result of new information, future developments or otherwise.

'/>"/>

SOURCE Takeda Pharmaceutical Company Limited Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
2. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
3. Takeda Announces New U.S. Leadership
4. Takeda submits new drug application for alogliptin (syr-322) in the US
5. Chemizon Announces Research Collaboration Expansion With Takeda
6. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
7. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
8. InfoLogix Completes $25 Million Senior Debt Financing
9. ConforMIS Completes Executive Team With Addition of CFO
10. Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study
11. Cardiva Medical, Inc. Completes $15.5 Million Private Equity Financing